Weight and Metabolic Outcomes in Naïve HIV Patients Treated with Integrase Inhibitor-Based Antiretroviral Therapy: A Systematic Review and Meta-Analysis

Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South Africa

(2023) Alana T. Brennan et al.   EClinicalMedicine

Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis

(2022) Ruojing Bai et al.   BMC INFECTIOUS DISEASES

Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug

(2022) Nikos Pantazis et al.   Viruses-Basel

Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents

(2021) Dathan M. Byonanebye   AIDS

Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: Republication

(2021) Shahini Shah et al.   Current Opinion in HIV and AIDS

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

(2021) Matthew J Page et al.   BMJ-British Medical Journal

Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naïve and Switch Scenarios in HIV-Infected Patients

(2021) Maria Saumoy et al.   Journal of Clinical Medicine

Integrase Inhibitor Use Associated with Weight Gain in Women and Incident Diabetes Mellitus

(2021) Archana Asundi et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Obesity and Weight Gain in Persons with HIV

(2020) Samuel S. Bailin et al.   Current HIV/AIDS Reports

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz

(2020) Rulan Griesel et al.   CLINICAL INFECTIOUS DISEASES

HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety

(2020) Kimberly K. Scarsi et al.   DRUGS

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial

(2020) Willem D F Venter et al.   Lancet HIV

Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

(2020) Alexandra Calmy et al.   Lancet HIV

Cabotegravir is Not Associated with Weight Gain in HIV-uninfected Individuals in HPTN 077

(2019) Raphael J Landovitz et al.   CLINICAL INFECTIOUS DISEASES

Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy

(2019) Kassem Bourgi et al.   CLINICAL INFECTIOUS DISEASES

Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project

(2019) Paola Bagella et al.   Infection and Drug Resistance

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

(2019) Willem D.F. Venter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1

(2019)   NEW ENGLAND JOURNAL OF MEDICINE

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2019) Hans-Jürgen Stellbrink et al.   Lancet HIV

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2019) David A Wohl et al.   Lancet HIV

RoB 2: a revised tool for assessing risk of bias in randomised trials

(2019) Jonathan A C Sterne et al.   BMJ-British Medical Journal

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

(2019) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

Weight gain and integrase inhibitors

(2019) Allison Ross Eckard et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

(2018) Josep M Llibre et al.   LANCET

The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality

(2018) Shejil Kumar et al.   Frontiers in Endocrinology

Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks

(2015) Romina Quercia et al.   CLINICAL DRUG INVESTIGATION

Weight Change After Antiretroviral Therapy and Mortality

(2015) B. Yuh et al.   CLINICAL INFECTIOUS DISEASES

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

(2015) Jean-Michel Molina et al.   NEW ENGLAND JOURNAL OF MEDICINE

Methods to estimate the between-study variance and its uncertainty in meta-analysis

(2015) Areti Angeliki Veroniki et al.   Research Synthesis Methods

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

(2014) Bonaventura Clotet et al.   LANCET

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO

(2014) Jean-Michel Molina et al.   Journal of the International AIDS Society

A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection

(2013) Jürgen K. Rockstroh et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

(2013) Francois Raffi et al.   LANCET

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET